Whilst you could argue the board has been poor to manage capital the science itself deserves support (as others here have said). There will be a time where we hopefully get value alignment but there’s equally been no argument that it’s taken CDH17 as the key asset into the clinic (as Jen Chow had always alluded to), a new CEO and a bio bear market to get to what I suspect will be a pivotal phase in the next 6-12 months.
Whilst you could argue the board has been poor to manage capital...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |